Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PHGE 
Biomx Inc (PHGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PHGE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.77% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.17M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 2 | Beta 1.43 | 52 Weeks Range 0.34 - 1.70 | Updated Date 08/15/2025 |
52 Weeks Range 0.34 - 1.70 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.11% | Return on Equity (TTM) -79.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20990302 | Price to Sales(TTM) - |
Enterprise Value 20990302 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.25 | Shares Outstanding 26176300 | Shares Floating 16227169 |
Shares Outstanding 26176300 | Shares Floating 16227169 | ||
Percent Insiders 19.08 | Percent Institutions 47.82 |
Upturn AI SWOT
Biomx Inc
Company Overview
History and Background
BioMX Inc. is a clinical-stage biotechnology company focused on developing microbiome-targeted therapies. Founded to harness the power of natural phages to target and eradicate specific harmful bacteria in the body.
Core Business Areas
- Therapeutic Programs: Developing phage-based therapies for chronic diseases like inflammatory bowel disease (IBD), acne, and primary sclerosing cholangitis (PSC).
- Research and Development: Focus on discovering and engineering novel phage cocktails and delivery methods.
Leadership and Structure
Key leaders drive scientific and business strategies. Led by a management team with expertise in biotechnology and pharmaceuticals. Board of Directors provides oversight and guidance.
Top Products and Market Share
Key Offerings
- BX001 (Inflammatory Bowel Disease - IBD): A phage cocktail targeting specific bacteria associated with IBD. It is currently in clinical trials. Competitors include companies developing small molecules and biologics for IBD such as Johnson & Johnson (JNJ) and AbbVie (ABBV).
- BX002 (Acne Vulgaris): A phage cocktail targeting Cutibacterium acnes, the bacteria associated with acne. It is currently in clinical trials. Competitors include Galderma (privately held) and companies developing topical treatments for acne such as Bausch Health (BHC).
- BX211 (Primary Sclerosing Cholangitis - PSC): A phage cocktail targeting specific bacteria associated with PSC. It is currently in preclinical development. There is limited direct competition due to the novel approach. Competitors developing therapeutics for PSC include Gilead (GILD).
Market Dynamics
Industry Overview
The microbiome therapeutics market is rapidly growing, driven by increasing understanding of the role of the microbiome in health and disease.
Positioning
BioMX is positioned as a leader in phage-based microbiome modulation, offering a targeted approach to disease treatment.
Total Addressable Market (TAM)
The total addressable market for microbiome therapeutics is estimated to reach billions of dollars. BiomX is positioned to capture a portion of this market with its targeted phage therapies.
Upturn SWOT Analysis
Strengths
- Proprietary phage technology platform
- Targeted approach to microbiome modulation
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Relatively early-stage development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing awareness of microbiome therapeutics
- Favorable regulatory environment
Threats
- Competition from other microbiome companies
- Clinical trial failures
- Regulatory hurdles
- Development of resistance to phages
Competitors and Market Share
Key Competitors
- CRSP
- SNY
- ARGX
Competitive Landscape
BiomX competes with other microbiome companies and traditional pharmaceutical companies. Its phage-based approach offers a potential advantage in terms of specificity and safety, but faces challenges in scalability and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily defined by advancements in clinical trials and partnerships.
Future Projections: Future growth depends on clinical trial success and potential partnerships. Analyst estimates vary widely due to the uncertainty of drug development.
Recent Initiatives: Focus on advancing clinical trials for BX001 and BX002. Exploring partnerships to expand development and commercialization.
Summary
BiomX is an early-stage biotech company with a novel phage-based approach to microbiome therapeutics. While it has a strong scientific foundation, it faces significant challenges in clinical development and funding. The company needs successful trial outcomes to attract partnerships and secure its long-term viability. Biomx is in a weak position until clinical trials are proven.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomx Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2019-03-13 | CEO & Director Mr. Jonathan Eitan Solomon MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.biomx.com |
Full time employees 52 | Website https://www.biomx.com | ||
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.